Wan S - Search Results

1

HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.

Wan S, Xi M, Zhao HB, Hua W, Liu YL, Zhou YL, Zhuo YJ, Liu ZZ, Cai ZD, Wan YP, Zhong WD. Wan S, et al. Among authors: wan yp. Pathol Res Pract. 2019 Aug;215(8):152464. doi: 10.1016/j.prp.2019.152464. Epub 2019 May 22. Pathol Res Pract. 2019. PMID: 31176575

2

Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.

Wan Y, Zeng ZC, Xi M, Wan S, Hua W, Liu YL, Zhou YL, Luo HW, Jiang FN, Zhong WD. Wan Y, et al. Among authors: wan s. Hum Pathol. 2015 Feb;46(2):295-303. doi: 10.1016/j.humpath.2014.10.027. Epub 2014 Nov 26. Hum Pathol. 2015. PMID: 25532941

3

Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.

Zhuo YJ, Xi M, Wan YP, Hua W, Liu YL, Wan S, Zhou YL, Luo HW, Wu SL, Zhong WD, Wu CL. Zhuo YJ, et al. Among authors: wan yp, wan s. Int J Mol Med. 2015 Apr;35(4):966-72. doi: 10.3892/ijmm.2015.2086. Epub 2015 Jan 30. Int J Mol Med. 2015. PMID: 25647485

4

Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.

Wan YP, Xi M, He HC, Wan S, Hua W, Zen ZC, Liu YL, Zhou YL, Mo RJ, Zhuo YJ, Luo HW, Jiang FN, Zhong WD. Wan YP, et al. Among authors: wan s. Oncol Res Treat. 2017;40(1-2):15-20. doi: 10.1159/000455145. Epub 2017 Jan 25. Oncol Res Treat. 2017. PMID: 28118628

5

Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.

Zhuo YJ, Liu ZZ, Wan S, Cai ZD, Xie JJ, Cai ZD, Song SD, Wan YP, Hua W, Zhong W, Wu CL. Zhuo YJ, et al. Among authors: wan yp, wan s. Biomed Pharmacother. 2018 Jun;102:531-538. doi: 10.1016/j.biopha.2018.03.079. Epub 2018 Mar 26. Biomed Pharmacother. 2018. PMID: 29587239

6

Correlation of SOX9 and NM23 genes with the incidence and prognosis of prostate cancer.

Xi M, Wan S, Hua W, Zhou Y, Jiang W, Hu J. Xi M, et al. Among authors: wan s. Oncol Lett. 2019 Feb;17(2):2296-2302. doi: 10.3892/ol.2018.9828. Epub 2018 Dec 12. Oncol Lett. 2019. Retraction in: Oncol Lett. 2024 Mar 04;27(5):191. doi: 10.3892/ol.2024.14324 PMID: 30675295 Free PMC article. Retracted.

7

TRIB1 induces macrophages to M2 phenotype by inhibiting IKB-zeta in prostate cancer.

Liu ZZ, Han ZD, Liang YK, Chen JX, Wan S, Zhuo YJ, Cai ZD, Deng YL, Lin ZY, Mo RJ, He HC, Zhong WD. Liu ZZ, et al. Among authors: wan s. Cell Signal. 2019 Jul;59:152-162. doi: 10.1016/j.cellsig.2019.03.017. Epub 2019 Mar 26. Cell Signal. 2019. PMID: 30926388

8

The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.

Wan S, Liu X, Hua W, Xi M, Zhou Y, Wan Y. Wan S, et al. Among authors: wan y. Bioengineered. 2021 Dec;12(1):1495-1504. doi: 10.1080/21655979.2021.1915725. Bioengineered. 2021. PMID: 33938397 Free PMC article.

9

Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.

Zhao HB, Zeng YR, Han ZD, Zhuo YJ, Liang YK, Hon CT, Wan S, Wu S, Dahl D, Zhong WD, Wu CL. Zhao HB, et al. Among authors: wan s. Cancer Sci. 2021 Oct;112(10):4365-4376. doi: 10.1111/cas.15062. Epub 2021 Aug 18. Cancer Sci. 2021. PMID: 34252262 Free PMC article.

10

[Retracted] Correlation of SOX9 and NM23 genes with the incidence and prognosis of prostate cancer.

Xi M, Wan S, Hua W, Zhou Y, Jiang W, Hu J. Xi M, et al. Among authors: wan s. Oncol Lett. 2024 Mar 4;27(5):191. doi: 10.3892/ol.2024.14324. eCollection 2024 May. Oncol Lett. 2024. PMID: 38495837 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,020 results

Search Page

Filters